| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-306SS | |||
| Azide and BSA Free | NBP2-80586 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-317SS | |||
| Azide and BSA Free | NBP2-80975 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-174SS | |||
| Azide and BSA Free | NBP2-80897 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-168SS | |||
| Azide and BSA Free | NBP2-80847 | |||
![Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunohistochemistry-NB100-306-img0005.jpg "Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.")
![Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Analysis of ATM-kinase, using ATM [p Ser1981] antibody (10H11.E12) [NB100-306]. Sample: Irradiated or peroxidated human fibroblasts. Observed molecular weight 370 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Western-Blot-NB100-306-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Human lymphoblastoid cells stained with ATM [p Ser1981] Antibody (10H11.E12). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunocytochemistry-Immunofluorescence-NB100-306-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - MCELNs decreased the DNA damage of H9C2 cells after radiation. Western blot images of p-ATM (NB100-306) and ATM (NB100-309) in H9C2 cells after 48 h of culture with indicated treatment. IR (-/+): 0/16 Gy X-ray; MCELNs (-/+): 0/10 ug/mL. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35509278/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb100-306_mouse-monoclonal-atm-p-ser1981-antibody-10h11-e12-2552023151493.jpg)
![Western Blot: RPA2 [p Ser33] Antibody [NB100-544] - Whole cell lysate (50 ug) from HeLa cells treated with 100 uM etoposide for 16 hours (+) or mock treated (-) cells. Antibody: Affinity purified rabbit anti-Phospho RPA32 (S33) antibody used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes. Lower panel: Rabbit anti-RPS3 antibody.](http://images.novusbio.com/fullsize/RPA2-[p-Ser33]-Antibody-Western-Blot-NB100-544-img0005.jpg "Western Blot: RPA2 [p Ser33] Antibody [NB100-544] - Whole cell lysate (50 ug) from HeLa cells treated with 100 uM etoposide for 16 hours (+) or mock treated (-) cells. Antibody: Affinity purified rabbit anti-Phospho RPA32 (S33) antibody used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes. Lower panel: Rabbit anti-RPS3 antibody.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: RPA2 [p Ser33] Antibody [NB100-544] - Active DNA end processing in late micronuclei compartments. Representative images (Upper panel) and quantification of RPA signal in MN compartments (Lower left) or RPA foci in nuclei (lower right) of post-IR OVCAR-8 cells after indicated treatments. Pro-resection genes (MRE11, BRCA1 and WDR70) were knockdown by specific siRNA. Percentage of positive RPA2-pS33 MN population was calculated after 36 h of IR treatment Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4347-0), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPA2-[p-Ser33]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-544-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: RPA2 [p Ser33] Antibody [NB100-544] - L.36 PDAC cells were treated two hours using 5 mM hydroxyurea to induce RPA32 Ser33 phosphorylation. The antibody produces clear nuclear staining of treated cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RPA2-[p-Ser33]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-544-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: RPA2 [p Ser33] Antibody [NB100-544] - Active DNA end processing in late micronuclei compartments. Detection and quantification of RPA2 phosphorylation (pSerine 33) and ssDNA by specific antibodies in MN compartments of OVCAR-8 cells 36 h after 2-Gy irradiation. Note the nuclear signals have reduced while those in MN were intense. n = 3 biological repeats. Error bars = s.d. **P < 0.01; ***P < 0.005 (t-test). Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4347-0), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RPA2-[p-Ser33]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-544-img0003.jpg)
![Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of mouse colon carcinoma CT26. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/SMC1-Antibody-Immunohistochemistry-Paraffin-NB100-204-img0008.jpg "Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of mouse colon carcinoma CT26. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB")
![Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/SMC1-Antibody-Immunohistochemistry-Paraffin-NB100-204-img0007.jpg)
![Simple Western: SMC1 Antibody [NB100-204] - Simple Western lane view shows a specific band for SMC1 in 0.5 mg/ml of Hek293 (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SMC1-Antibody-Simple-Western-NB100-204-img0006.jpg)
![SMC1 Antibody [NB100-204] - Detection of human and mouse SMC1 by western blot. Samples: Whole cell lysate (50 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-SMC1 antibody NB100-204 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds.Previous](http://images.novusbio.com/fullsize/SMC1-Antibody-NB100-204-img0009.jpg)
![SMC1 Antibody [NB100-204] - Detection of human SMC1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-SMC1 antibody NB100-204 used for IP at 6 ug per reaction. SMC1 was also immunoprecipitated by rabbit anti-SMC1 recombinant monoclonal antibody NB2-76412. For blotting immunoprecipitated SMC1, NB100-204 was used at 1:1000. Detection: Chemiluminescence with an exposure time time of 10 seconds.](http://images.novusbio.com/fullsize/SMC1-Antibody-NB100-204-img0010.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Western-Blot-NB100-220-img0007.jpg "Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.")
![Immunocytochemistry/Immunofluorescence: ATM Antibody (5C2) [NB100-220] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: ATM protein stained by ATM antibody (5C2) [NB100-220] diluted at 1:200. Blue: Hoechst 33342 staining. Scale bar = 10 um.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Immunocytochemistry-Immunofluorescence-NB100-220-img0004.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 and S6). Cell lines were exposed to 10 Gy and protein extracts were obtained 1h and 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using beta-actin as loading control. Image collected and cropped by CiteAb from the following publication (www.dx.plos.org/10.1371/journal.pone.0005475) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Western-Blot-NB100-220-img0008.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis.A. Representative images of 3MC-fibrosarcomas immunostained for Arf, p53 & p21 (see also Table 1). The upper & middle rows are representative of the large majority of fibrosarcomas developed in wild-type (upper) & Atm-null (middle) mice, which are consistent with a mutant p53 (i.e. strongly positive for p53 & negative for p21). The lower row is representative of the fibrosarcomas developed in Arf-null mice, which are consistent with a functional p53 (i.e. very weakly positive for p53 & positive for p21). B. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 & S6). Cell lines were exposed to 10 Gy & protein extracts were obtained 1h & 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using beta -actin as loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241612655.jpg)
![Immunohistochemistry: ATM Antibody (5C2) [NB100-220] - Limited role of Atm in p53-mediated tumor suppression & DNA damage response in chemically-induced fibrosarcomas.A. Mice of the indicated genotypes, wt (n = 15), p53-super (n = 16), Atm-null (n = 9), p53-super/Atm-null (n = 13) & Arf-null (n = 12), were injected intramuscularly with 3-methyl-cholanthrene (3MC) & tumour development was monitored. Kaplan-Meier tumour-free curves were obtained & statistical significant differences (logrank test) were found for wt vs. p53-super (p<0.005), Atm-null vs. p53-super/Atm-null (p<0.001) & Arf-null vs. wt (p<0.0001). No significant differences were found for wt vs. Atm-null (p = 0.11), or p53-super vs. p53-super/Atm-null (p = 0.18). B. Quantification of the persistent DNA damage response ( gamma H2AX), proliferation (Ki67), & apoptosis (activated caspase-3) in 3MC-fibrosarcomas generated in mice of the indicated genotypes. Quantifications are relative to the 3MC-fibrosarcomas in wild-type mice. Values correspond to the average & standard deviation (n = 5 per genotype). Examples of the immunostainings are shown in the panels at the right. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-3102024165717.jpg)
![Immunocytochemistry/ Immunofluorescence: ATM Antibody (5C2) [NB100-220] - BAG3P209L aggregation leads to co-aggregation of proteasomal substrates. a Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Scale bar = 5 μm. b Suppression of GFP-HttQ74 aggregation of cells expressing a control, FLAG-BAG3WT or FLAG-BAG3P209L. Western blot against indicated antibodies is shown. c Quantification of GFP-HttQ74 aggregation of experiments similar to b. Relative percentage of SDS-insoluble protein levels are shown. Data represents the mean & standard deviation of three independent experiments. d Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Left column BAG3, middle column ubiquitin & right column is the merge of BAG3 (green), ubiquitin (red), & DAPI (blue). Scale bar = 5 μm. e Fractionation of HEK293 cells expressing HSPB8, a control or BAG3WT or BAG3P209L, together with either Ub-R-GFP or GFP-ODC (ornithine decarboxylase). Western blot against GFP, FLAG (BAG3), Myc (HSPB8), & tubulin are shown. f Fractionation of HEK293 cells expressing HSPB8 & indicated BAG3 variants. Western blot using ubiquitin (FK2) & tubulin antibodies are shown. The same samples as in Fig. 5e have been used, loading control is therefore the same. Source data are provided as a Source data file Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30559338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241553206.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Increased levels of IFI16 protein in WI-38 cells reduce hTERT levels and inhibit telomerase activity. Total protein extracts prepared from WI-38 cells, either transfected with control (pCMV) vector (lane 1) or pCMV-IFI16 plasmid (lane 2), were subjected to immunoblotting using antibodies specific to the indicated proteins. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008569), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Western-Blot-NB100-317-img0019.jpg "Western Blot: TERT Antibody (2C4) [NB100-317] - Increased levels of IFI16 protein in WI-38 cells reduce hTERT levels and inhibit telomerase activity. Total protein extracts prepared from WI-38 cells, either transfected with control (pCMV) vector (lane 1) or pCMV-IFI16 plasmid (lane 2), were subjected to immunoblotting using antibodies specific to the indicated proteins. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008569), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: TERT Antibody (2C4) [NB100-317] - Human Pancreatic carcinoma showing strong staining of tumor cells.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Immunohistochemistry-Paraffin-NB100-317-img0017.jpg)
![Flow Cytometry: TERT Antibody (2C4) [NB100-317] - An intracellular stain was performed on A431 cells with TERT Antibody [2C4] NB100-317 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgM (H+L) Cross-Adsorbed Secondary Antibody, AlexaFluor 488.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Flow-Cytometry-NB100-317-img0020.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - 1:500 dilution on MJ90 cells.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Western-Blot-NB100-317-img0015.jpg)
![Immunohistochemistry-Paraffin: TERT Antibody (2C4) [NB100-317] - Normal human pancreas showing moderate staining of exocrine cells and a subset of islets of Langerhans.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Immunohistochemistry-Paraffin-NB100-317-img0016.jpg)
![Flow Cytometry: TERT Antibody (2C4) [NB100-317] - An intracellular stain was performed on Jurkat cells with TERT Antibody (2C4) NB100-317 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse IgM Alexa Fluor 488-conjugated secondary antibody.](http://images.novusbio.com/fullsize/TERT-Antibody-2C4-Flow-Cytometry-NB100-317-img0018.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - The interaction of TERT with p65 in murine macrophages.(a) Expression of p65 in liver tissue was analyzed by IHC staining analysis. Representative views from each group were presented (original magnification, ×40). (b) The protein expression & phosphorylation of p65 at Ser 536 were observed in liver tissue & KCs isolated from the liver by WB. The results are shown as relative expression against control expression without treatment. Values represent means ± SD. (n = 4 in CD-fed group, n=6 in EtOH-fed group) *P < 0.05, **P < 0.01 vs liver tissues of CD-fed group. #P < 0.05, ##P < 0.01 vs KCs of CD-fed group. (c) p65 protein expression & phosphorylation were analyzed in total cell lysates of M0, M1 & M2 macrophages by WB. The results are shown as relative expression against control expression without treatment. Data shown are the mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 vs control. (d) Representative colocalization of TERT with macrophage p65 immunoreactivity in liver tissue by using the double immunofluorescent (IF) analysis. (e) Effect of TERT on p65 expression & activation in LPS-stimulated RAW 264.7 cells. Expression of p65 & phosphorylated p65 were determined by WB. (f) Effect of PDTC on p65 expression in LPS-stimulated RAW 264.7 cells. Expression of p65 was determined by WB. (g) Expression of TERT upon treatment with PDTC was determined by WB in LPS-stimulated RAW 264.7 cells. (h) Effect of PDTC on the expression of M1 macrophage biomarkers in LPS-stimulated RAW 264.7 cells. The results are shown as relative expression against control expression without treatment. Data shown are the mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 vs control. #P < 0.05, ##P < 0.01 vs LPS-treated group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-31020241555214.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Reduced expression levels of IFI16 protein in human normal diploid fibroblasts after treatment with histone deacetylase inhibitor are associated with increased expression of hTERT & increased telomerase activity.(A) Total RNA isolated from untreated (control, lane 1) or CGK1026 (10 µM for 24 h, lane 2) treated young WI-38 fibroblasts was subjected cDNA synthesis followed by semi-quantitative PCR using a pair of primer specific to the IFI16, hTERT, or actin. As a positive control, we used RNA from human HT1080, a human fibrosarcoma cell line. (B) Total RNA isolated from untreated (control) or CGK1026 (10 µM for 24 h; treated) treated young WI-38 fibroblasts was subjected cDNA synthesis, followed by quantitative real-time PCR using the TaqMan assay for the hTERT gene. Results are mean values of triplicate experiments & error bars represent standard deviation (**p<0.005). (C & D) Total protein extracts prepared from untreated (lane 1) or CGK1026 (10 µM for 24 h; treated) treated young WI-38 fibroblasts were subjected to immunoblotting using antibodies specific to the indicated proteins. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008569), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-31020241682124.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Plastic expression of TERT in murine macrophages.RAW264.7 cells were treated with LPS (1 μg/mL) for 24 h to polarize M1 macrophage phenotype, while treatment with IL-4 (15 ng/mL) for 24 h induced M2 macrophage phenotype. One population into another was transformed by culturing M1 macrophages with IL-4 & M2 macrophages with LPS, respectively. (a) The mRNA levels of M1 macrophage markers (TNF-alpha , IL-1 beta , CCL2 & NOS2) & M2 macrophage markers (Arg-1, IL-10, Mrc2 & CD163) were analyzed by real-time PCR. (b) The plastic expression of TERT in murine macrophage polarization was determined by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. Data shown are the mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 vs control. (c) The expression of TERT in RAW264.7 macrophages polarization was analyzed by immunofluorescence (IF) assay. Representative views from each group were presented (original magnification, ×20). (d) RAW264.7 cells were treated with IFN-gamma (10 ng/mL) for 24 h alone or in combination with LPS. The production of TERT was determined by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. Data shown are the mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 vs control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-310202415532028.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Reduced expression levels of IFI16 protein in human normal diploid fibroblasts after treatment with histone deacetylase inhibitor are associated with increased expression of hTERT & increased telomerase activity.(A) Total RNA isolated from untreated (control, lane 1) or CGK1026 (10 µM for 24 h, lane 2) treated young WI-38 fibroblasts was subjected cDNA synthesis followed by semi-quantitative PCR using a pair of primer specific to the IFI16, hTERT, or actin. As a positive control, we used RNA from human HT1080, a human fibrosarcoma cell line. (B) Total RNA isolated from untreated (control) or CGK1026 (10 µM for 24 h; treated) treated young WI-38 fibroblasts was subjected cDNA synthesis, followed by quantitative real-time PCR using the TaqMan assay for the hTERT gene. Results are mean values of triplicate experiments & error bars represent standard deviation (**p<0.005). (C & D) Total protein extracts prepared from untreated (lane 1) or CGK1026 (10 µM for 24 h; treated) treated young WI-38 fibroblasts were subjected to immunoblotting using antibodies specific to the indicated proteins. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008569), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-310202415523921.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Effect of alcohol on TERT expression in liver tissues & KCs during ALD development.(a) TERT expression in liver tissues was performed by IHC analysis. Representative views from each group were presented (original magnification, ×40). (b) Total TERT mRNA & protein levels in liver tissue were analyzed by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. (c) Representative colocalization of TERT with macrophage CD68 immunoreactivity in liver tissue by using the double immunofluorescent (IF) analysis. (d) Total TERT mRNA & protein levels in KCs isolated from the liver were analyzed by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. (e) Quantification of telomerase activity (TA) in CD-fed mice & EtOH-fed mice. RNase treatment or heat inactivation of KCs isolated from the liver of EtOH-fed mice served as negative controls for the TA assay. All quantitative data are presented as mean ± SD percentage increase compared with CD-fed group (n = 4 in CD-fed group, n = 6 in EtOH-fed group) *P < 0.05, **P < 0.01 vs CD-fed group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-310202415532045.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Effect of TERT silencing on murine M1 macrophage polarization.TERT siRNA & GV144-TERT were transiently transfected into LPS-treated RAW264.7 cells, respectively. (a) The endogeous TERT levels were detected by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. (b) The mRNA levels of M1 macrophages biomarkers including TNF-alpha , IL-1 beta , NOS2 & CCL2 were detected by real-time PCR. The results are shown as relative expression against control expression without treatment. (c) The secretion of proinflammatory cytokines including TNF-alpha , IL-1 beta , IL-6 & IL-12 were determined by ELISA. (d) TERT successful over-expression was verified by real-time PCR & western blot in LPS-stimulated RAW 264.7 cells. The results are shown as relative expression against control expression without treatment. (e) The mRNA levels of M1 macrophages biomarkers were detected by real-time PCR. The results are shown as relative expression against control expression without treatment. (f) The secretion of proinflammatory cytokines were determined by ELISA. Data shown are the mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 vs control group. #P < 0.05, ##P < 0.01 vs LPS-treated group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-310202415532074.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - IFI16 inhibits c-Myc-stimulated transcription & hTERT expression in HeLa cells.(A) Total protein extracts prepared from HeLa cells infected with control retrovirus (lane 1) or a virus encoding IFI16 protein (lane 2) were subjected to immunoblotting using antibodies specific to the indicated proteins. (B) Sub-confluent cultures of HeLa cells were transfected with pMyc-TA-luc reporter plasmid (1.0 µg) along with a second pRL-TK reporter plasmid (0.2 µg) & an empty plasmid (pCMV; column 1), a plasmid encoding c-Myc (column 2 & 4), a plasmid encoding IFI16 (column 3), or both plasmids encoding c-Myc & increasing amounts of the plasmid encoding IFI16 protein (column 5 & 6). After 44–48 h of transfections, cells were lysed & the lysates were analyzed for dual luciferase activity. Normalized relative luciferase activity in control cells is indicated as 1.0. (C) Total protein extracts prepared from HeLa cells infected with control retrovirus (lane 1) or a virus encoding antisense to IFI16 mRNA (lanes 2) were subjected to immunoblotting using antibodies specific to the indicated proteins. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0008569), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-31020241553737.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Effect of alcohol on TERT expression in liver tissues & KCs during ALD development.(a) TERT expression in liver tissues was performed by IHC analysis. Representative views from each group were presented (original magnification, ×40). (b) Total TERT mRNA & protein levels in liver tissue were analyzed by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. (c) Representative colocalization of TERT with macrophage CD68 immunoreactivity in liver tissue by using the double immunofluorescent (IF) analysis. (d) Total TERT mRNA & protein levels in KCs isolated from the liver were analyzed by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. (e) Quantification of telomerase activity (TA) in CD-fed mice & EtOH-fed mice. RNase treatment or heat inactivation of KCs isolated from the liver of EtOH-fed mice served as negative controls for the TA assay. All quantitative data are presented as mean ± SD percentage increase compared with CD-fed group (n = 4 in CD-fed group, n = 6 in EtOH-fed group) *P < 0.05, **P < 0.01 vs CD-fed group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-31020241683943.jpg)
![Western Blot: TERT Antibody (2C4) [NB100-317] - Effect of alcohol on TERT expression in vitro.Acute alcohol treatment of RAW 264.7 cells can be achieved with 25 mM EtOH for 24 h. (a) TERT mRNA & protein expression in EtOH-stimulated RAW 264.7 cells were analyzed by real-time PCR & western blot. The results are shown as relative expression against control expression without treatment. The values represent means ± SD. *P < 0.05, **P < 0.01 vs control. #P<0.05, ##P<0.01 vs EtOH-treated group. (b) Effect of alcohol on M1 macrophage markers (TNF-alpha , IL-1 beta , CCL2 & NOS2) in RAW 264.7 cells without or with LPS stimulation. (c) Effect of alcohol on M2 macrophage markers (Arg-1, IL-10, Mrc2 & CD163) in RAW 264.7 cells without or with LPS stimulation. (d) Effect of alcohol on the production of cytokines including TNF-alpha , IL-1 beta , IL-6, IL-12 & IL-10 in RAW 264.7 cells without or with LPS stimulation. The results are shown as line chart. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26725521), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-317_mouse-monoclonal-tert-antibody-2c4-310202415532026.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0011.jpg "Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Staining of sections from a wild type mouse testis taken at P11 were probed with NB200-174 (green). Sections were stained with DAPI to reveal the position of cell nuclei (blue).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Immunohistochemistry-NB200-174-img0008.jpg)
![Flow (Intracellular): p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - An intracellular stain was performed on HEK293 cells with p14ARF (5-C3-1) antibody NB200-174 (blue) and a matched isotype control MAB0061 (orange) [A]. An intracellular stain was also performed on THP-1 (known homozygous deletion of gene, PMID: 19635138) cells to ensure antibody specificity [B]. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Goat Anti-Rat F(ab)2 IgG (H+L) APC-conjugated Antibody (F0113, R&D Systems). *Note: This antibody recognizes both human (p14ARF) and mouse (p19ARF) versions of the protein.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Flow-Intracellular-NB200-174-img0010.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Aberrantly upregulated p19ARF/CDKN2A antagonizes TFH differentiation and survival. p19ARF/CDKN2A and Bcl6 interaction capacity. WT or mutant p19ARF/CDKN2A was co-transfected with WT Bcl6 expression vector into 293T cells. Cell lysates were immunoprecipitated with anti-Bcl6 and then immunoblotted with anti-p19ARF/CDKN2A. Data are representative of two experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-07853-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0012.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Analysis of endogenous p19Arf. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Detection of p19Arf. Wild type mouse embryo fibroblasts (MEF) at passage 5 (panels 1, 2) and NIH3T3 cells, which have deleted the Arf gene (panels 3, 4) were probed with NB200-17 and nuclear stain (overlay in panels 2 and 4).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Knockout-Validated-NB200-174-img0009.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-31020241621829.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205122.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Loss of P19Arf enhances tumor growth & primary lung fibroblasts induce p19Arf in response to leucine deprivation (LD). (A) Graph of sarcoma (SKPY) tumor volume on the indicated days. SKPY cells were injected into the flank of WT & p19Arf-null mice. Tumor volume was measured by caliper. N=7 mice/WT cohort & N=15 mice/p19Arf−/− cohort. (B) Western blot for p19Arf protein expression in WT & Arf-null fibroblasts after LD for the indicated days. Densitometric quantification of p19Arf protein expression relative to beta -tubulin is shown on right. (C) qPCR for p19Arf mRNA in WT or p19Arf−/− fibroblasts during LD for the indicated days. (D) Representative immunofluorescence images for P19Arf subcellular localization on the indicated days after LD in WT or p19Arf−/− ALFs. Quantification of nuclear p19Arf is shown in graph on right. (E) Western blot analysis of phospho-eIF2 alpha (P-eIF2 alpha ) & total eIF2 alpha expression in WT & p19Arf-null murine ALFs during LD for the indicated days. Graph quantifies intensity of P-eIF2 alpha expression relative to day 0. beta -Tubulin used as loading control. (F) Western blot analysis of P-eIF2 alpha expression in WT & p19Arf−/− ALFs upon treatment with a GCN2 inhibitor (GCN2-IN-1; A-92 1 µM in DMSO) during overnight LD. Actin used as a loading control. Quantification of P-eIF2 alpha expression relative to total eIF2 alpha . N=3; *, P<0.05; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34994382), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205128.jpg)
![Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416203717.jpg)
![Flow Cytometry: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free - Conducted the antibody trial with two different dilutions of p19ARF/CDKN2A Antibody (5-C3-1) [PE] (Catalog # NB200-174PE) (1:500 and 1:100) and compared them to an IgG control which was also PE labelled. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-312202414314910.png)
![Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Western-Blot-NB100-513-img0004.jpg "Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds")
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of human ovarian carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0002.jpg)
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of mouse renal cell carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0001.jpg)
![Immunoprecipitation: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Immunoprecipitation-NB100-513-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunohistochemistry-NB100-473-img0008.jpg "Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.")
![<b>Genetic Strategies Validation. </b>Western Blot: Mre11 Antibody (12D7) [NB100-473] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] diluted at 1:500. HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody. A band appears at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0010.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein by western blot analysis. A. 30 ug 293T whole cell extract. B. 30 ug whole cell extract of human Mre11-transfected 293T cells. 7.5% SDS-PAGE. Mre11 antibody [12D7] (NB100-473). HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. Bands are prominent at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Analysis of Mre11 antibody (12D7) on lymphoblastoid cells. Dilution 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein at nucleus by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Mre11 stained by Mre11 antibody [12D7] (NB100-473).Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mouse fibroblasts stained with Mre11 Antibody (12D7). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0020.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] (NB100-473) diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nb100-473_mouse-monoclonal-mre11-antibody-12d7-91020242091437.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - Mouse intestine. RBPMS stained by RBPMS antibody diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/RBPMS-Antibody-Immunohistochemistry-Paraffin-NBP2-20112-img0012.jpg "Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - Mouse intestine. RBPMS stained by RBPMS antibody diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.")
![Western Blot: RBPMS Antibody [NBP2-20112] - Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with RBPMS antibody (NBP2-20112) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242091455.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded mouse lymph node.RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242021960.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded rat colon.RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-910202420131234.jpg)
![Immunocytochemistry/ Immunofluorescence: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunofluorescent analysis.Sample: A549 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242011420.jpg)
![RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunofluorescent analysis.Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-immunocytochemistry-immunofluorescence-26112025182700.jpg)
![RBPMS antibody detects RBPMS protein by immunohistochemical analysis. Samples: Paraffin-embedded mouse retina.Green: RBPMS protein stained by RBPMS antibody (NBP2-20112) diluted at 1:250.Red: beta Tubulin 3/ Tuj1, a marker, stained by beta Tubulin 3/ Tuj1 antibody [GT1338] diluted at 1:500.Blue: Fluoroshield with DAPI . br>Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-immunohistochemistry-paraffin-261120251819361.jpg)
![Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Western-Blot-NB100-168-img0002.jpg "Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.")
![Immunocytochemistry/Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT (Green) in Hela cells using NB100-168 at a 1:50 dilution. Nuclei (Blue) are counterstained using Hoechst 33258.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunocytochemistry-Immunofluorescence-NB100-168-img0004.jpg)
![Immunohistochemistry-Paraffin: MGMT Antibody (MT 23.2) [NB100-168] - IHC analysis of a formalin fixed paraffin-embedded (FFPE) human kidney using 1:2000 conc. of MGMT antibody (clone MT 23.2) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining of MGMT was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunohistochemistry-Paraffin-NB100-168-img0013.jpg)
![Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on HeLa cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Cytometry-NB100-168-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-MGMT (MT 23.2) NB100-168 at a 1:200 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was counterstained with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunocytochemistry-Immunofluorescence-NB100-168-img0006.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control NBP2-27231 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0008.jpg)
![Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in Human Jurkat Cell Line by Flow Cytometry. Human Jurkat cell line was stained with Mouse Anti- MGMT Monoclonal Antibody (Catalog # NB100-168, filled histogram), or Mouse IgG2B isotype control (Catalog # MAB0041, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Cytometry-NB100-168-img0011.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Raji cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control NBP2-27231AF647 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0012.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0014.jpg)
![Simple Western: MGMT Antibody (MT 23.2) [NB100-168] - Simple Western lane view shows a specific band for MGMT in 0.2 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Simple-Western-NB100-168-img0005.jpg)
![Western Blot: Histone H2AX Antibody [NB100-638] - Downregulation of the transcription factors Slug and ZEB1 reverses the EMT programme induced by H2A.X deficiency. Immunoblot analysis of EMT markers in HCT116 parental cells (WT) and H2A.X knockout cells (KO) transfected for 3 days with siRNA control (siC) or with a pool of siSLUG and siZEB1 (siS/Z) with tubulin-loading controls. H2A.X knockout cells were generated using CRISPR/Cas9 system for precise deletion of the H2A.X gene. cl.5, clone #5; and cl.6, clone #6. Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/ncomms10711), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Histone-H2AX-Antibody-Western-Blot-NB100-638-img0006.jpg "<b>Biological Strategies Validation. </b>Western Blot: Histone H2AX Antibody [NB100-638] - Downregulation of the transcription factors Slug and ZEB1 reverses the EMT programme induced by H2A.X deficiency. Immunoblot analysis of EMT markers in HCT116 parental cells (WT) and H2A.X knockout cells (KO) transfected for 3 days with siRNA control (siC) or with a pool of siSLUG and siZEB1 (siS/Z) with tubulin-loading controls. H2A.X knockout cells were generated using CRISPR/Cas9 system for precise deletion of the H2A.X gene. cl.5, clone #5; and cl.6, clone #6. Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/ncomms10711), licensed under a CC-BY license.")
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Immunocytochemistry/Immunofluorescence: Histone H2AX Antibody [NB100-638] - Asynchronous wild-type (+/+) and H2AX knockout (-/-) mouse embryonic fibroblasts. Antibody used at 2 ug/ml.](http://images.novusbio.com/fullsize/Histone-H2AX-Antibody-Immunocytochemistry-Immunofluorescence-NB100-638-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Histone H2AX Antibody [NB100-638] - Human 293T and wild-type (+/+) or H2AX knockout (-/-) mouse embryonic fibroblasts. Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/Histone-H2AX-Antibody-Western-Blot-NB100-638-img0004.jpg)
![Western Blot: Histone H2AX Antibody [NB100-638] - Downregulation of the transcription factors Slug and ZEB1 reverses the EMT programme induced by H2A.X deficiency. Control cells (shCTRL) and cells silenced for H2A.X (shH2A.X) were transfected for 3 days with control siRNA (siC) or with a pool of siSLUG and siZEB1 (siS/Z). Immunoblot analysis of EMT markers was performed using tubulin as loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/ncomms10711), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Histone-H2AX-Antibody-Western-Blot-NB100-638-img0005.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Histone H2AX Antibody [NB100-638] - H2A.X re-expression inhibits EMT and promotes metastatic colonization in the lung. Immunoblot analysis of EMT markers in HCT116 parental cells (WT), H2A.X knockout cells (KO) and H2A.X knockout cells in which H2A.X expression was restored (KO+H2A.X), utilizing actin as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/doifinder/10.1038/ncomms10711), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Histone-H2AX-Antibody-Western-Blot-NB100-638-img0007.jpg)
![Western Blot: Histone H2AX Antibody [NB100-638] - Knockdown of CAPER induces DSB proteins ATM & H2AX & leads to apoptosis in MDA-MB-231 cells(A) H2AX phosphorylation on ser139 is significantly increased (upper right quadrant population) in MDA-MB-231 cells after CAPER knockdown as represented by Muse Cell Analyzer plots (3-fold, p < 0.001, n = 3). (B) The increase in gamma H2AX was also validated through western blot analysis (2.5-fold, p < 0.01, n = 3). ATM phosphorylation on serine1981 is significantly upregulated after knockdown of CAPER expression (5-fold, p < 0.05, n = 3). (C) CAPER knockdown resulted in an increased level of caspase-3/7 activation through decreasing live cells (1.2-fold, p < 0.001, n = 3), while increasing apoptotic (7.5-fold, p < 0.001, n = 3), apoptotic/dead (6.5-fold, p < 0.001, n = 3), & dead (3-fold, p < 0.05, n = 3) cell populations. Interestingly, MDA-MB-231 cells expressing CAPER knockdown displayed no significant changes in any of the phases of the cell cycle (p = NS, n = 8, for G1, S & G2/M phases) compared to CTL shRNA (Figure 7C right panels). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30100993), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-638_rabbit-polyclonal-histone-h2ax-antibody-3102024155370.jpg)